Novanta (NOVT) Q2 Revenue Rises 2.2%
Novanta (NASDAQ:NOVT), a specialist in precision technologies for the medical and advanced industrial sectors, posted its financial results for Q2 2025 on August 5, 2025. The company exceeded expectations on both GAAP revenue and adjusted (non-GAAP) earnings per share, with GAAP revenue reaching $241.0 million (versus a $237.97 million estimate) and adjusted EPS (non-GAAP) of $0.76 (above the consensus of $0.73). However, free cash flow (non-GAAP) and net income (GAAP) declined significantly as the company absorbed the costs of acquisitions, restructuring initiatives, and trade disruptions. Overall, the period showed resilience in high-growth markets like advanced surgery and robotics, though underlying organic revenue contracted by 2.1% and operational volatility remained a concern.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Novanta designs and manufactures core technologies for medical devices and advanced industrial equipment. Its main product lines include motion control components, sensors, optical systems, and radio-frequency identification (RFID) hardware and software. These products are often sold to original equipment manufacturers (OEMs) that integrate Novanta’s technologies into surgical tools, diagnostic instruments, robotics, and automation machinery.
Source Fool.com
